Community Associated Methicillin-Resistant Staphylococcus Aureus: A Review

Michael J. Rybak, PharmD; Kerry L. LaPlante, PharmD

Disclosures

Pharmacotherapy. 2005;25(1):74-85. 

In This Article

Conclusion

Evidence suggests that CA-MRSA—the newest staphylococcal threat—will be increasingly prevalent in the near future. Moreover, although most strains are now susceptible to many non-β-lactam antibiotics, this may change due to exposure to multiple antimicrobials in various settings. Epidemiologic studies are needed to specify the patient populations likely to harbor this pathogen. Alternative treatment options to β-lactams must be assessed under investigational trial conditions before specific treatment guidelines can be recommended.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....